InSilico Medicine Cayman TopCo (INSILICO) filed its Monthly Return for the period ended 30 April 2026, showing no movement in authorised or issued share capital and confirming compliance with Hong Kong’s public-float requirements.

Authorised Capital • Authorised share count remained at 1.27 billion ordinary shares with a par value of USD 0.0000005, representing total authorised capital of USD 635.

Issued Shares and Public Float • Issued shares stayed unchanged at 572.40 million. • The company held no treasury shares, leaving total issued shares also at 572.40 million. • INSILICO affirmed that the minimum 15 percent public float prescribed at listing was satisfied as at month-end.

Equity Incentive Plans • Pre-IPO equity incentive plans recorded the lapse of 187,500 options, reducing outstanding options to 27.77 million. • A post-IPO share option scheme adopted on 15 December 2025 remained untouched during the month, with 24.16 million options available for future grants. • Outstanding restricted share units totalled 2.37 million under pre- and post-IPO RSU schemes, with no new shares issued and no treasury share movements.

Capital Movements • No new shares were issued, repurchased, or cancelled during April 2026. • Total funds raised from option exercises in the month were USD 0.

Governance Confirmation The filing, signed by Chairman and CEO Aleksandrs Zavoronkovs, confirms that all share-related activities complied with Hong Kong Listing Rules and other applicable regulations.

INSILICO’s steady share structure and confirmed float sufficiency position the company for continued orderly trading on the Hong Kong Stock Exchange.